Long-Acting Muscarinic Antagonists(LAMA)

PreclinicalSmall molecule

Long-Acting Muscarinic Antagonists(LAMA) is one of 44 small molecule programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

GlucocorticoidCompleted

Chronic Obstructive Pulmonary DiseasePreclinical

Active, not recruiting

GlucocorticoidPreclinical

Completed

Competition

Competitive Landscape

120 competitors in Chronic Obstructive Pulmonary Disease

#DrugCompanyPhaseTrials

EXDENSUR

GGlaxo Dba Glaxosmithkline

Phase 3

2 2

Lunsekimig

Sanofi

Phase 3

3 3

Tozorakimab

AstraZeneca

Phase 3

2 4

CM310

KKeymed Biosciences Co.Ltd

Phase 3

1 5

Sildenafil ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

2 6

Astegolimab

Roche

Phase 3

3 7

Titrated Oxygen

RRigshospitalet, Denmark

Phase 3

1 8

HSK39004

Haisco Pharmaceutical Group Co., Ltd.

Phase 2

2 9

Calciferol

Duragesic

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease1 trial

Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT05393245·19,467 enrolled

Chronic Obstructive Airway Disease1 trial

A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT04172701·9,284 enrolled

Glucocorticoid1 trial

Personalized Variable Versus Fixed Dose Glucocorticoid Therapy in AECOPD

Completed·—·N/A·NCT02147015·248 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Long-Acting Muscarinic Antagonists(LAMA). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Long-Acting Muscarinic Antagonists(LAMA) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Long-Acting Muscarinic Antagonists(LAMA). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Boehringer Ingelheim

Long-Acting Muscarinic Antagonists(LAMA)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease1 trial

Chronic Obstructive Airway Disease1 trial

Glucocorticoid1 trial

References

Drug Info

Quick Facts

Related News